# A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

> **NCT07341152** · PHASE1 · COMPLETED · sponsor: **Latigo Biotherapeutics** · enrollment: 14 (actual)

## Conditions studied

- Pain Management

## Interventions

- **DRUG:** LTG-001 SDD
- **DRUG:** LTG-001 Formulation A Prototype 1
- **DRUG:** LTG-001 Formulation B Prototype 2
- **DRUG:** LTG-001 Formulation B prototype 2

## Key facts

- **NCT ID:** NCT07341152
- **Lead sponsor:** Latigo Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-06
- **Primary completion:** 2025-11-17
- **Final completion:** 2025-11-17
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07341152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07341152, "A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07341152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*